Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?
In spite of tremendous advances in advanced ovarian cancer management through the past decade, notably owing to surgical expertise and novel combination molecules (including bevacizumab and PARP inhibitors), the optimal initial sequential strategy remains a major concern. Indeed, following seminal c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/14/3556 |
| _version_ | 1797589959149879296 |
|---|---|
| author | Stanislas Quesada Quentin Dominique Thomas Pierre-Emmanuel Colombo Frederic Fiteni |
| author_facet | Stanislas Quesada Quentin Dominique Thomas Pierre-Emmanuel Colombo Frederic Fiteni |
| author_sort | Stanislas Quesada |
| collection | DOAJ |
| description | In spite of tremendous advances in advanced ovarian cancer management through the past decade, notably owing to surgical expertise and novel combination molecules (including bevacizumab and PARP inhibitors), the optimal initial sequential strategy remains a major concern. Indeed, following seminal clinical trials, primary cytoreductive surgery (PCS) followed by adjuvant systemic therapy and interval cytoreductive surgery (ICS) following neoadjuvant chemotherapy (NACT) have been positioned as validated alternatives with distinct pros and cons, although a definite response is still unassessed. In clinical practice, decisions between PCS and ICS rely on multilayer parameters: the tumor itself, the patient, and the health structure. In this state-of-the-art review, we will discuss the current evidence based on clinical trials and real-world data and highlight the remaining questions, including the fittest positioning of PCS vs. ICS and the optimal number of NACT cycles; subsequently, we will discuss current axes of research such as dedicated clinical trials and more global perspectives. These ongoing strategies and perspectives could contribute to improving the patient journey through personalized medicine. |
| first_indexed | 2024-03-11T01:13:32Z |
| format | Article |
| id | doaj.art-55ea4468880948ff9bebc272e6d36a8b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T01:13:32Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-55ea4468880948ff9bebc272e6d36a8b2023-11-18T18:40:44ZengMDPI AGCancers2072-66942023-07-011514355610.3390/cancers15143556Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?Stanislas Quesada0Quentin Dominique Thomas1Pierre-Emmanuel Colombo2Frederic Fiteni3Institut Régional du Cancer de Montpellier (ICM), 34298 Montpellier, FranceInstitut Régional du Cancer de Montpellier (ICM), 34298 Montpellier, FranceInstitut Régional du Cancer de Montpellier (ICM), 34298 Montpellier, FranceMedical Oncology Department, University Hospital of Nîmes, 30900 Nîmes, FranceIn spite of tremendous advances in advanced ovarian cancer management through the past decade, notably owing to surgical expertise and novel combination molecules (including bevacizumab and PARP inhibitors), the optimal initial sequential strategy remains a major concern. Indeed, following seminal clinical trials, primary cytoreductive surgery (PCS) followed by adjuvant systemic therapy and interval cytoreductive surgery (ICS) following neoadjuvant chemotherapy (NACT) have been positioned as validated alternatives with distinct pros and cons, although a definite response is still unassessed. In clinical practice, decisions between PCS and ICS rely on multilayer parameters: the tumor itself, the patient, and the health structure. In this state-of-the-art review, we will discuss the current evidence based on clinical trials and real-world data and highlight the remaining questions, including the fittest positioning of PCS vs. ICS and the optimal number of NACT cycles; subsequently, we will discuss current axes of research such as dedicated clinical trials and more global perspectives. These ongoing strategies and perspectives could contribute to improving the patient journey through personalized medicine.https://www.mdpi.com/2072-6694/15/14/3556epithelial ovarian cancerprimary cytoreductive surgeryinterval cytoreductive surgeryprognosismedicosurgical strategy |
| spellingShingle | Stanislas Quesada Quentin Dominique Thomas Pierre-Emmanuel Colombo Frederic Fiteni Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet? Cancers epithelial ovarian cancer primary cytoreductive surgery interval cytoreductive surgery prognosis medicosurgical strategy |
| title | Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet? |
| title_full | Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet? |
| title_fullStr | Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet? |
| title_full_unstemmed | Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet? |
| title_short | Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet? |
| title_sort | optimal first line medico surgical strategy in ovarian cancers are we there yet |
| topic | epithelial ovarian cancer primary cytoreductive surgery interval cytoreductive surgery prognosis medicosurgical strategy |
| url | https://www.mdpi.com/2072-6694/15/14/3556 |
| work_keys_str_mv | AT stanislasquesada optimalfirstlinemedicosurgicalstrategyinovariancancersarewethereyet AT quentindominiquethomas optimalfirstlinemedicosurgicalstrategyinovariancancersarewethereyet AT pierreemmanuelcolombo optimalfirstlinemedicosurgicalstrategyinovariancancersarewethereyet AT fredericfiteni optimalfirstlinemedicosurgicalstrategyinovariancancersarewethereyet |